SAN DIEGO, Nov. 3, 2014 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update
Conference Call for the third quarter 2014 on Monday, November 10, 2014 at 4:30 p.m. ET/1:30 p.m.
PT. Dr. Helen Torley,
President and Chief Executive Officer, will lead the call. On the
same date post-market, Halozyme will release financial results for
the third quarter 2014.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the close of the call. To access the webcast, please log
on to www.halozyme.com approximately fifteen minutes prior to
the call to register, download and install any necessary audio
software. For those without access to the Internet, the live call
may be accessed by phone by dialing (866) 710-0179 (domestic
callers) or (334) 323-7224 (international callers) using passcode
769890. A telephone replay will be available shortly after the call
by dialing (877) 919-4059 (domestic callers) or (334) 323-0140
(international callers) using replay ID number 45298549.
About Halozyme
Halozyme Therapeutics is a
biopharmaceutical company dedicated to developing and
commercializing innovative products that advance patient care. With
a diversified portfolio of enzymes that target the extracellular
matrix, the Company's research focuses primarily on a family of
human enzymes, known as hyaluronidases, which increase the
dispersion and absorption of biologics, drugs and fluids.
Halozyme's pipeline addresses therapeutic areas, including
oncology, diabetes and dermatology that have significant unmet
medical need today. The Company markets Hylenex®
recombinant (hyaluronidase human injection) and has
partnerships with Roche, Pfizer and Baxter. Halozyme is headquartered in San
Diego, CA. For more information on how we are innovating,
please visit our corporate website at www.halozyme.com.
Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Media Contact:
Susan Neath
Francis
212-301-7182
sfrancis@wcgworld.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
SOURCE Halozyme Therapeutics, Inc.